Research Paper Volume 13, Issue 9 pp 13006—13022

A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with 68Ga-labeled PD-L1 targeted nanobody

PET imaging of tumor-bearing models. (A) Static images at 1, 1.5, and 2h after injection of 2.5 MBq of 68Ga-NOTA-Nb109 (n=3, tumors indicated by the yellow arrow). (B) The uptake of 68Ga-NOTA-Nb109 in tumors according to quantification analysis of PET images. (C) PD-L1 immunohistochemical staining of tumors (n=5, scale bar =2 mm in the left column and 200 μm in right column). ***P D) Biodistribution of 68Ga-NOTA-Nb109 in major organs at 1 and 2 h (n=5).

Figure 4. PET imaging of tumor-bearing models. (A) Static images at 1, 1.5, and 2h after injection of 2.5 MBq of 68Ga-NOTA-Nb109 (n=3, tumors indicated by the yellow arrow). (B) The uptake of 68Ga-NOTA-Nb109 in tumors according to quantification analysis of PET images. (C) PD-L1 immunohistochemical staining of tumors (n=5, scale bar =2 mm in the left column and 200 μm in right column). ***P <0.001. (D) Biodistribution of 68Ga-NOTA-Nb109 in major organs at 1 and 2 h (n=5).